GLP-1 Prescriptions for Obesity Rise Sharply in U.S. Children Under 12
A new study finds a 310-fold increase in GLP-1 prescriptions for children ages 8 to 11 with obesity since 2019, though use remains rare.
GLP-1 Use in Young Children With Obesity Is Increasing Rapidly
A study led by NYU Langone Health found that prescriptions for glucagon-like peptide-1 (GLP-1) receptor agonists in U.S. children ages 8 to 11 with obesity rose from 0.03% in 2019 to 9.3% in 2026. This represents a 310-fold increase over 7.5 years.
Despite this sharp rise, the absolute number of children in this age group receiving GLP-1 medications remains low compared to the total population of children with obesity.
Study Details and Who Is Receiving GLP-1s
The study, published in Pediatrics, analyzed national prescription data for children ages 8 to 11 with obesity and without diabetes. Between 2019 and June 2026, 20,282 children in this age group were prescribed GLP-1 drugs such as Saxenda, Wegovy, and Zepbound.
Older children (ages 12 to 17) with obesity were slightly more likely to be prescribed GLP-1s (0.9%) than younger children (0.6%). Girls and children with severe obesity or obesity-related conditions were more likely to receive these medications.
Metabolic Health Context and Access Disparities
Most children prescribed GLP-1s had severe obesity (93.7%) and at least one obesity-related health issue (65.2%), such as high cholesterol, high blood pressure, or sleep apnea. A quarter of these children were prediabetic.
Children living in upper-income communities were 55% more likely to be prescribed GLP-1s than those in lower-income areas, highlighting early signs of access gaps.
Clinical Implications and Ongoing Questions
GLP-1 drugs can help with weight loss, appetite suppression, and improved blood sugar regulation in children with obesity, according to the study authors. Clinical guidelines allow their use in children as young as 8.
Researchers emphasize the importance of long-term monitoring to track safety and effectiveness, as well as the need to address disparities in access to these medications.
Limitations and Considerations for Families
While GLP-1 use is rising, it remains rare among young children with obesity. The study notes that many families and clinicians may have concerns about starting these medications in children.
Long-term risks and benefits are still being studied, and the decision to use GLP-1s should involve careful discussion with healthcare providers.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Related Articles
Continuous Glucose Monitoring Links Glucose Spikes to Heart Risks
Framingham Heart Study data show adults without diabetes who spend more time above 140 mg/dL...
Read article MetabolismGut Microbe Molecule Vaccenic Acid Activates Liver Receptor LRH-1
Researchers identified vaccenic acid as a bacterial ligand for receptor LRH-1, showing reduced...
Read article MetabolismDiabetes Distress Assessment Guidelines Released by EASD
The EASD published evidence-based diabetes distress assessment guidelines in Diabetologia,...
Read article MetabolismWhole Grain Intake of 60 to 100 Grams Daily Improves Heart Markers
A review of 87 clinical trials in the European Heart Journal found consuming 60 to 100 grams of...
Read articlePartner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.